{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Covid-19", "anti-inflammation", "anti-viral", "herbs", "phytochemical"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "36125969", "DateCompleted": {"Year": "2022", "Month": "11", "Day": "22"}, "DateRevised": {"Year": "2022", "Month": "12", "Day": "07"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "10", "Day": "10"}], "Language": ["eng"], "ELocationID": ["10.1002/cbdv.202200655"], "Journal": {"ISSN": "1612-1880", "JournalIssue": {"Volume": "19", "Issue": "11", "PubDate": {"Year": "2022", "Month": "Nov"}}, "Title": "Chemistry & biodiversity", "ISOAbbreviation": "Chem Biodivers"}, "ArticleTitle": "The Efficacy of Traditional Medicinal Plants in Modulating the Main Protease of SARS-CoV-2 and Cytokine Storm.", "Pagination": {"StartPage": "e202200655", "MedlinePgn": "e202200655"}, "Abstract": {"AbstractText": ["Selected traditional medicinal plants exhibit therapeutic effects in coronavirus disease (Covid-19) patients. This review aims to identify the phytochemicals from five traditional medicinal plants (Glycyrrhiza glabra, Nigella sativa, Curcuma longa, Tinospora cordifolia and Withania somnifera) with high potential in modulating the main protease (Mpro) activity and cytokine storm in Covid-19 infection. The Mpro binding affinity of 13 plant phytochemicals were in the following order: Withanoside II>withanoside IV>withaferin A>\u03b1-hederin>withanoside V>sitoindoside IX>glabridin>liquiritigenin, nigellidine>curcumin>glycyrrhizin>tinocordiside>berberine. Among these phytochemicals, glycyrrhizin, withaferin A, curcumin, nigellidine and cordifolioside A suppressed SARS-CoV-2 replication and showed stronger anti-inflammatory activities than standard Covid-19 drugs. Both preclinical and clinical evidences supported the development of plant bioactive compounds as Mpro inhibitors."], "CopyrightInformation": "\u00a9 2022 Wiley-VHCA AG, Zurich, Switzerland."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Biosciences, Faculty of Science and Engineering, University of Nottingham Malaysia, 43500, Selangor, Malaysia."}], "LastName": "Choe", "ForeName": "Jomin", "Initials": "J"}, {"Identifier": ["0000-0002-5888-9856"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Bioscience, Faculty of Medicine, Bioscience and Nursing, MAHSA University, 42610, Selangor, Malaysia."}], "LastName": "Har Yong", "ForeName": "Phaik", "Initials": "P"}, {"Identifier": ["0000-0002-9423-7206"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Biosciences, Faculty of Science and Engineering, University of Nottingham Malaysia, 43500, Selangor, Malaysia."}], "LastName": "Xiang Ng", "ForeName": "Zhi", "Initials": "Z"}], "GrantList": [{"Agency": "School of Biosciences, University of Nottingham Malaysia", "Country": ""}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Chem Biodivers", "NlmUniqueID": "101197449", "ISSNLinking": "1612-1872"}, "ChemicalList": [{"RegistryNumber": "EC 3.4.-", "NameOfSubstance": "Peptide Hydrolases"}, {"RegistryNumber": "IT942ZTH98", "NameOfSubstance": "Curcumin"}, {"RegistryNumber": "6FO62043WK", "NameOfSubstance": "Glycyrrhizic Acid"}, {"RegistryNumber": "0", "NameOfSubstance": "Phytochemicals"}, {"RegistryNumber": "0", "NameOfSubstance": "Protease Inhibitors"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "SARS-CoV-2"}, {"QualifierName": ["chemistry"], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": [], "DescriptorName": "Cytokine Release Syndrome"}, {"QualifierName": [], "DescriptorName": "Peptide Hydrolases"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Curcumin"}, {"QualifierName": [], "DescriptorName": "Glycyrrhizic Acid"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Phytochemicals"}, {"QualifierName": ["chemistry"], "DescriptorName": "Protease Inhibitors"}, {"QualifierName": [], "DescriptorName": "Molecular Docking Simulation"}, {"QualifierName": [], "DescriptorName": "COVID-19 Drug Treatment"}]}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "K. Roedl, G. S\u00f6ffker, D. Fischer, J. M\u00fcller, D. Westermann, M. Issleib, S. Kluge, D. Jarczak, \u2018Effects of COVID-19 on in-hospital cardiac arrest: incidence, causes, and outcome - a retrospective cohort study\u2019, Scand. J. Trauma, Resusc. Emerg. Med. 2021, 29, 1-11."}, {"Citation": "V. Kumar, K. U. Doshi, W. H. Khan, A. S. Rathore, \u2018COVID-19 pandemic: mechanism, diagnosis, and treatment\u2019, J. Chem. Technol. Biotechnol. 2021, 96, 299-308."}, {"Citation": "F. Coperchini, L. Chiovato, L. Croce, F. Magri, M. Rotondi, \u2018The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system\u2019, Cytokine Growth Factor Rev. 2020, 53, 25-32."}, {"Citation": "W. Dai, B. Zhang, X. M. Jiang, H. Su, J. Li, Y. Zhao, X. Xie, Z. Jin, J. Peng, F. Liu, C. Li, Y. Li, F. Bai, H. Wang, X. Cheng, X. Cen, S. Hu, X. Yang, J. Wang, X. Liu, G. Xiao, H. Jiang, Z. Rao, L. K. Zhang, Y. Xu, H. Yang, H. Liu, \u2018Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease\u2019, Science 2020, 368, 1331-1335."}, {"Citation": "H. M. Mengist, X. Fan, T. Jin, \u2018Designing of improved drugs for COVID-19: Crystal structure of SARS-CoV-2 main protease Mpro\u2019, Signal Transduction Targeted Ther. 2020, 5, 1-2."}, {"Citation": "A. A. Rabaan, S. H. Al-Ahmed, J. Muhammad, A. Khan, A. A. Sule, R. Tirupathi, A. A. Mutair, S. Alhumaid, A. Al-Omari, M. Dhawan, \u2018Role of inflammatory cytokines in COVID-19 patients: A review on molecular mechanisms, immune functions, immunopathology and immunomodulatory drugs to counter cytokine storm\u2019, Vaccine 2021, 9, 436."}, {"Citation": "R. L. Kruse, \u2018Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China\u2019, F1000Research 2020, 9."}, {"Citation": "Z. Jin, X. Du, Y. Xu, Y. Deng, M. Liu, Y. Zhao, B. Zhang, X. Li, L. Zhang, C. Peng, Y. Duan, J. Yu, L. Wang, K. Yang, F. Liu, R. Jiang, X. Yang, T. You, X. Liu, X. Yang, F. Bai, H. Liu, X. Liu, L. W. Guddat, W. Xu, G. Xiao, C. Qin, Z. Shi, H. Jiang, Z. Rao, H. Yang, \u2018Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors\u2019, Nature 2020, 582, 289-293."}, {"Citation": "G. N. Trivedi, J. Karlekar, H. Dhameliya, H. Panchal, \u2018A review on the novel coronavirus disease based on In-silico analysis of various drugs and target proteins\u2019, J. Pure Appl. Microbiol. 2020, 14, 849-860."}, {"Citation": "S. Bharadwaj, E. I. Azhar, M. A. Kamal, L. H. Bajrai, A. Dubey, K. Jha, U. Yadava, S. G. Kang, V. D. Dwivedi, \u2018SARS-CoV-2 Mpro inhibitors: identification of anti-SARS-CoV-2 Mpro compounds from FDA approved drugs\u2019, J. Biomol. Struct. Dyn. 2020, 1-16."}, {"Citation": "G. Magro, \u2018SARS-CoV-2 and COVID-19: Is interleukin-6 (IL-6) the \u2018culprit lesion'of ARDS onset? What is there besides Tocilizumab? SGP130Fc\u2019, Cytokine 2020, 2, 100029."}, {"Citation": "L. Zhang, D. Lin, X. Sun, U. Curth, C. Drosten, L. Sauerhering, S. Becker, K. Rox, R. Hilgenfeld, \u2018Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved a-ketoamide inhibitors\u2019, Science 2020, 368, 409-412."}, {"Citation": "B. Adhikari, B. P. Marasini, B. Rayamajhee, B. R. Bhattarai, G. Lamichhane, K. Khadayat, A. Adhikari, S. Khanal, N. Parajuli, \u2018Potential roles of medicinal plants for the treatment of viral diseases focusing on COVID-19: A review\u2019, Phytother. Res. 2021, 35, 1298-1312."}, {"Citation": "T. U. Singh, S. Parida, M. C. Lingaraju, M. Kesavan, D. Kumar, R. K. Singh, \u2018Drug repurposing approach to fight COVID-19\u2019, Pharmacol. Rep. 2020, 72, 1-30."}, {"Citation": "P. Shree, P. Mishra, C. Selvaraj, S. K. Singh, R. Chaube, N. Garg, Y. B. Tripathi, \u2018Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants-Withania somnifera (Ashwagandha), Tinospora cordifolia (Giloy) and Ocimum sanctum (Tulsi)-a molecular docking study\u2019 , J. Biomol. Struct. Dyn. 2020, 40, 1-14."}, {"Citation": "M. Boozari, H. Hosseinzadeh, \u2018Natural products for COVID-19 prevention and treatment regarding to previous coronavirus infections and novel studies\u2019, Phytother. Res. 2021, 35, 864-876."}, {"Citation": "T. Mohammad, A. Shamsi, S. Anwar, M. Umair, A. Hussain, M. T. Rehman, M. F. AlAjmi, A. Islam, M. I. Hassan, \u2018Identification of high-affinity inhibitors of SARS-CoV-2 main protease: Towards the development of effective COVID-19 therapy\u2019, Virus Res. 2020, 288, 198102."}, {"Citation": "M. Soy, G. Keser, P. Atag\u00fcnd\u00fcz, F. Tabak, I. Atag\u00fcnd\u00fcz, S. Kayhan, \u2018Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment\u2019, Clin. Rheumatol. 2020, 39, 2085-2094."}, {"Citation": "X. Li, Q. Qiu, M. Li, H. Lin, S. Cao, Q. Wang, Z. Chen, W. Jiang, W. Zhang, Y. Huang, H. Luo, L. Luo, \u2018Chemical composition and pharmacological mechanism of ephedra-glycyrrhiza drug pair against coronavirus disease 2019 (COVID-19)\u2019, Aging 2021, 13, 4811-4830."}, {"Citation": "S. Garg, A. Anand, Y. Lamba, A. Roy, \u2018Molecular docking analysis of selected phytochemicals against SARS-CoV-2 Mpro receptor\u2019, Vegetos 2020, 33, 766-781."}, {"Citation": "G. Pastorino, L. Cornara, S. Soares, F. Rodrigues, M. B. P. Oliveira, \u2018Liquorice (Glycyrrhiza glabra): A phytochemical and pharmacological review\u2019, Phytother. Res. 2018, 32, 2323-2339."}, {"Citation": "M. Parvaiz, K. Hussain, S. Khalid, N. Hussnain, N. Iram, Z. Hussain, M. A. Ali, \u2018A review: Medicinal importance of Glycyrrhiza glabra L.(Fabaceae family)\u2019, Global J. Pharmacol. 2014, 8, 8-13."}, {"Citation": "M. Jiang, S. Zhao, S. Yang, X. Lin, X. He, X. Wei, Q. Song, R. Li, C. Fu, J. Zhang, \u2018An \u2018essential herbal medicine\u2019-Licorice: A review of phytochemicals and its effects in combination preparations\u2019, J. Ethnopharmacol. 2020, 249, 112439."}, {"Citation": "V. Srivastava, A. Yadav, P. Sarkar, \u2018Molecular docking and ADMET study of bioactive compounds of Glycyrrhiza glabra against main protease of SARS-CoV2\u2019, Mater. Today: Proc. 2020., 49, 2999-3007."}, {"Citation": "J. H. Chandra, H. Gunasekaran, \u2018Screening of phytochemical, antimicrobial and antioxidant activity of glycyrrhiz glabra root extract\u2019, J. Environ. Biol. 2017, 38, 161-165."}, {"Citation": "M. H. Sampangi-Ramaiah, R. Vishwakarma, R. U. Shaanker, \u2018Molecular docking analysis of selected natural products from plants for inhibition of SARS-CoV-2 main protease\u2019, Curr. Sci. 2020, 118, 1087-1092."}, {"Citation": "D. Armanini, C. Fiore, J. Bielenberg, C. Sabbadin, L. Bordin, \u2018Coronavirus-19: Possible Therapeutic Implications of Spironolactone and Dry Extract of Glycyrrhiza glabra L. (Licorice)\u2019, Front. Pharmacol. 2020, 11, 558418."}, {"Citation": "I. I. Hejazi, M. A. Beg, M. A. Imam, F. Athar, A. Islam, \u2018Glossary of phytoconstituents: Can these be repurposed against SARS CoV-2? A quick in silico screening of various phytoconstituents from plant Glycyrrhiza glabra with SARS CoV-2 main protease\u2019, Food Chem. Toxicol. 2021, 150, 112057."}, {"Citation": "L. van de Sand, M. Bormann, M. Alt, L. Schipper, C. S. Heilingloh, E. Steinmann, D. Todt, U. Dittmer, C. Elsner, O. Witzke, \u2018Glycyrrhizin Effectively Inhibits SARS-CoV-2 Replication by Inhibiting the Viral Main Protease\u2019, Viruses 2021, 13, 609."}, {"Citation": "M. Umadevi, R. Rajeswari, C. S. Rahale, S. Selvavenkadesh, R. Pushpa, K. S. Kumar, D. Bhowmik, \u2018Traditional and medicinal uses of Withania somnifera\u2019, The Pharm. Innov. 2012, 1, 102-110."}, {"Citation": "M. K. Tripathi, P. Singh, S. Sharma, T. P. Singh, A. Ethayathulla, P. Kaur, \u2018Identification of bioactive molecule from Withania somnifera (Ashwagandha) as SARS-CoV-2 main protease inhibitor\u2019, J. Biomol. Struct. Dyn. 2021, 39, 5668-5681."}, {"Citation": "A. Saggam, K. Limgaokar, S. Borse, P. Chavan-Gautam, S. Dixit, G. Tillu, B. Patwardhan, \u2018Withania somnifera (L.) Dunal: Opportunity for Clinical Repurposing in COVID-19 Management\u2019, Front. Pharmacol. 2021, 12, 623795."}, {"Citation": "H. Sudeep, K. Gouthamchandra, K. Shyamprasad, \u2018Molecular docking analysis of Withaferin A from Withania somnifera with the Glucose regulated protein 78 (GRP78) receptor and the SARS-CoV-2 main protease\u2019, Bioinformation 2020, 16, 411-417."}, {"Citation": "M. Dhawan, M. Parmar, K. Sharun, R. Tiwari, M. Bilal, K. Dhama, \u2018Medicinal and therapeutic potential of withanolides from Withania somnifera against COVID-19\u2019, J. Appl. Pharmacol. 2021, 11, 6-13."}, {"Citation": "F. Babaei, M. Nassiri-Asl, H. Hosseinzadeh, \u2018Curcumin (a constituent of turmeric): New treatment option against COVID-19\u2019, Food Sci. Nutr. 2020, 8, 5215-5227."}, {"Citation": "D. M. Teli, M. B. Shah, M. T. Chhabria, \u2018In silico Screening of Natural Compounds as Potential Inhibitors of SARS-CoV-2 Main Protease and Spike RBD: Targets for COVID-19\u2019, Front. Mol. Biosci. 2021, 7, 599079."}, {"Citation": "S. Khan, F. Siddiqui, S. Jain, G. Sonwane, \u2018Discovery of potential inhibitors of SARS-CoV-2 (COVID-19) Main Protease (Mpro) from Nigella Sativa (black seed) by molecular docking study\u2019, Coronaviruses 2021, 2, 384-402."}, {"Citation": "P. Halder, U. Pal, P. Paladhi, S. Dutta, P. Paul, S. Pal, D. Das, A. Ganguly, I. Dutta, S. Mandal, \u2018Evaluation of potency of the selected bioactive molecules from Indian medicinal plants with MPro of SARS-CoV-2 through in silico analysis\u2019, J. Ayurveda and Integr. Med. 2022, 13, 100449."}, {"Citation": "N. Sharma, D. Ahirwar, D. Jhade, S. Gupta, \u2018Medicinal and phamacological potential of Nigella sativa: a review\u2019, Ethnobot. leafl. 2009, 2009, 11."}, {"Citation": "N. Choudhary, M. Siddiqui, S. Azmat and S. Khatoon, \u2018Tinospora cordifolia: ethnobotany, phytopharmacology and phytochemistry aspects\u2019, Int. J. Pharm. Sci. Res. 2013, 4, 891-899."}, {"Citation": "A. Balkrishna, S. K. Solleti, S. Verma, A. Varshney, \u2018Application of humanized zebrafish model in the suppression of SARS-CoV-2 spike protein induced pathology by tri-herbal medicine coronil via cytokine modulation\u2019, Molecules 2020, 25, 5091."}, {"Citation": "L. Sapra, A. Bhardwaj, Z. Azam, D. Madhry, B. Verma, S. Rathore, R. K. Srivastava, \u2018Phytotherapy for treatment of cytokine storm in COVID-19\u2019, Front. Biosci. (Landmark Ed) 2021, 26, 51-57."}, {"Citation": "J.-X. Zhou, M. Wink, \u2018Evidence for anti-inflammatory activity of isoliquiritigenin, 18\u03b2 glycyrrhetinic acid, ursolic acid, and the traditional chinese medicine plants Glycyrrhiza glabra and Eriobotrya japonica, at the molecular level\u2019, Medicine 2019, 6, 55."}, {"Citation": "J. Cinatl, B. Morgenstern, G. Bauer, P. Chandra, H. Rabenau and H. Doerr, \u2018Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus\u2019, Lancet 2003, 361, 2045-2046."}, {"Citation": "H. Murck, \u2018Symptomatic protective action of glycyrrhizin (licorice) in COVID-19 infection?\u2019, Front. Immunol. 2020, 11, 1239."}, {"Citation": "P. Luo, D. Liu, J. Li, \u2018Pharmacological perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19\u2019, Int. J. Antimicrob. Agents 2020, 55, 105995."}, {"Citation": "A. M. Tolah, L. M. Altayeb, T. A. Alandijany, V. D. Dwivedi, S. A. El-Kafrawy, E. I. Azhar, \u2018Computational and In Vitro Experimental Investigations Reveal Anti-Viral Activity of Licorice and Glycyrrhizin against Severe Acute Respiratory Syndrome Coronavirus 2\u2019, Pharmaceuticals 2021, 14, 1216."}, {"Citation": "Z. X. Ng, U. R. Kuppusamy, I. Tajunisah, K. C. S. Fong, K. H. Chua, \u2018Investigation of SLC2A1 26177A/G gene polymorphism via high resolution melting curve analysis in Malaysian patients with diabetic retinopathy\u2019, J. Diabetes Complicat. 2012, 26, 388-392."}, {"Citation": "P. Gowda, S. Patrick, S. D. Joshi, R. K. Kumawat, E. Sen, \u2018Glycyrrhizin prevents SARS-CoV-2 S1 and Orf3a induced high mobility group box 1 (HMGB1) release and inhibits viral replication\u2019, Cytokine 2021, 142, 155496."}, {"Citation": "E. Shawky, A. A. Nada, R. S. Ibrahim, \u2018Potential role of medicinal plants and their constituents in the mitigation of SARS-CoV-2: identifying related therapeutic targets using network pharmacology and molecular docking analyses\u2019, RSC Adv. 2020, 10, 27961-27983."}, {"Citation": "C. Fiore, M. Eisenhut, E. Ragazzi, G. Zanchin, D. Armanini, \u2018A history of the therapeutic use of liquorice in Europe\u2019, J. Ethnopharmacol. 2005, 99, 317-324."}, {"Citation": "B. A. Mir, J. Khazir, N. A. Mir, T.-U. Hasan, S. Koul, \u2018Botanical, chemical and pharmacological review of Withania somnifera (Indian ginseng): an ayurvedic medicinal plant\u2019, Indian J. Drugs Dis. 2012, 1, 147-160."}, {"Citation": "S. K. Verma, A. Kumar, \u2018Therapeutic uses of Withania somnifera (Ashwagandha) with a note on withanolides and its pharmacological actions\u2019, Asian J. Pharm. Clin. Res. 2011, 4, 1-14."}, {"Citation": "A. Balkrishna, S. Haldar, H. Singh, P. Roy, A. Varshney, \u2018Coronil, a tri-herbal formulation, attenuates spike-protein-mediated SARS-CoV-2 viral entry into human alveolar epithelial cells and pro-inflammatory cytokines production by inhibiting spike protein-ACE-2 interaction\u2019, J. Inflammation Res. 2021, 14, 869-884."}, {"Citation": "M. A. Morsy, S. S. Patel, A. A. El-Sheikh, J. K. Savjani, A. B. Nair, J. N. Shah, K. N. Venugopala, \u2018Computational and biological comparisons of plant steroids as modulators of inflammation through interacting with glucocorticoid receptor\u2019, Mediators Inflammation 2019, 2019, 3041438."}, {"Citation": "D. Kanchibhotla, S. Subramanian, R. M. R. Kumar, K. V. Hari, M. Pathania, \u2018An In-vitro evaluation of a polyherbal formulation, against SARS-CoV-2\u2019, J. Ayurveda Integr. Med. 2022, 13, 100581."}, {"Citation": "H. Ti, Z. Mai, Z. Wang, W. Zhang, M. Xiao, Z. Yang, P. Shaw, \u2018Bisabolane-type sesquiterpenoids from Curcuma longa L. exert anti-influenza and anti-inflammatory activities through NF-\u03baB/MAPK and RIG-1/STAT1/2 signaling pathways\u2019, Food Funct. 2021, 12, 6697-6711."}, {"Citation": "M. Bormann, M. Alt, L. Schipper, L. van de Sand, V. T. K. Le-Trilling, L. Rink, N. Heinen, R. J. Madel, M. Otte, K. Wuensch, \u2018Turmeric root and its bioactive ingredient curcumin effectively neutralize SARS-CoV-2 In Vitro\u2019, Viruses 2021, 13, 1914."}, {"Citation": "V. Sagar, A. H. Kumar, \u2018Efficacy of natural compounds from Tinospora cordifolia against SARS-CoV-2 protease, surface glycoprotein and RNA polymerase\u2019, Virology 2020, 1-10."}, {"Citation": "A. Warowicka, R. Nawrot, A. Go\u017adzicka-J\u00f3zefiak, \u2018Antiviral activity of berberine\u2019, Arch. Virol. 2020, 165, 1935-1945."}, {"Citation": "K. Kumano, M. A. Kanak, P. B. Saravanan, J. P. Blanck, Y. Liu, S. Vasu, M. Lawrence, B. Naziruddin, \u2018Withaferin A inhibits lymphocyte proliferation, dendritic cell maturation In Vitro and prolongs islet allograft survival\u2019, Sci. Rep. 2021, 11, 10661."}, {"Citation": "D. S. Mandlik, A. G. Namdeo, \u2018Pharmacological evaluation of Ashwagandha highlighting its healthcare claims, safety, and toxicity aspects\u2019, J. Diet. Suppl. 2021, 18, 183-226."}, {"Citation": "R. P. Yadav, G. Tarun, C. Roshan, P. Yadav, \u2018Versatility of turmeric: A review the golden spice of life\u2019, J. Pharmacogn. Phytochem. 2017, 6, 41-46."}, {"Citation": "S. Balaji, B. Chempakam, \u2018Toxicity prediction of compounds from turmeric (Curcuma longa L)\u2019, Food Chem. Toxicol. 2010, 48, 2951-2959."}, {"Citation": "R. S. Ahmad, M. B. Hussain, M. T. Sultan, M. S. Arshad, M. Waheed, M. A. Shariati, S. Plygun, M. H. Hashempur, \u2018Biochemistry, safety, pharmacological activities, and clinical applications of turmeric: a mechanistic review\u2019, J. Evidence-Based Complementary Altern. Med. 2020, 2020, 7656919."}, {"Citation": "S. Irshad, A. Muazzam, Z. Shahid, M. B. Dalrymple, \u2018Curcuma longa (Turmeric): An auspicious spice for antibacterial, phytochemical and antioxidant activities\u2019, Pak. J. Pharm. Sci. 2018, 31, 2689-2696."}, {"Citation": "C. M. Mbadiko, C. L. Inkoto, B. Z. Gbolo, E. M. Lengbiye, J. T. Kilembe, A. Matondo, D. T. Mwanangombo, E. M. Ngoyi, G. N. Bongo, C. M. Falanga, \u2018A mini review on the phytochemistry, toxicology and antiviral activity of some medically interesting Zingiberaceae species\u2019, J. Complement. Altern. Med. Res. 2020, 9, 44-56."}, {"Citation": "M. Sankar, B. Ramachandran, B. Pandi, N. Mutharasappan, V. Ramasamy, P. G. Prabu, G. Shanmugaraj, Y. Wang, B. Muniyandai, S. Rathinasamy, \u2018In silico Screening of Natural Phytocompounds Towards Identification of Potential Lead Compounds to Treat COVID-19\u2019, Front. Mol. Biosci. 2021, 8."}, {"Citation": "S. Gupta, A. K. Singh, P. P. Kushwaha, K. S. Prajapati, M. Shuaib, S. Senapati, S. Kumar, \u2018Identification of potential natural inhibitors of SARS-CoV2 main protease by molecular docking and simulation studies\u2019, J. Biomol. Struct. Dyn. 2021, 39, 4334-4345."}, {"Citation": "M. A. A. Ibrahim, A. H. M. Abdelrahman, T. A. Hussien, E. A. A. Badr, T. A. Mohamed, H. R. El-Seedi, P. W. Pare, T. Efferth, M. E. F. Hegazy, \u2018In silico drug discovery of major metabolites from spices as SARS-CoV-2 main protease inhibitors\u2019, Comput. Biol. Med. 2020, 126, 104046."}, {"Citation": "G. F. Parisi, G. Carota, C. Castruccio Castracani, M. Spampinato, S. Manti, M. Papale, M. Di Rosa, I. Barbagallo, S. Leonardi, \u2018Nutraceuticals in the Prevention of Viral Infections, including COVID-19, among the Pediatric Population: A Review of the Literature\u2019, Int. J. Mol. Sci. 2021, 22, 2465."}, {"Citation": "S. Han, J. Xu, X. Guo, M. Huang, \u2018Curcumin ameliorates severe influenza pneumonia via attenuating lung injury and regulating macrophage cytokines production\u2019, Clin. Exp. Pharmacol. Physiol. 2018, 45, 84-93."}, {"Citation": "S. Maiti, A. Banerjee, A. Nazmeen, M. Kanwar, S. Das, \u2018Active-site Molecular docking of Nigellidine with nucleocapsid-NSP2-MPro of COVID-19 and to human IL1R-IL6R and strong antioxidant role of Nigella-sativa in experimental rats\u2019, J. Drug Targeting 2020, 30, 1-23."}, {"Citation": "S. Ahmad, H. W. Abbasi, S. Shahid, S. Gul, S. W. Abbasi, \u2018Molecular docking, simulation and MM-PBSA studies of nigella sativa compounds: a computational quest to identify potential natural antiviral for COVID-19 treatment\u2019, J. Biomol. Struct. Dyn. 2021, 39, 4225-4233."}, {"Citation": "M. A. Farag, H. A. Gad, A. G. Heiss, L. A. Wessjohann, \u2018Metabolomics driven analysis of six Nigella species seeds via UPLC-qTOF-MS and GC-MS coupled to chemometrics\u2019, Food Chem. 2014, 151, 333-342."}, {"Citation": "M. N. Islam, K. S. Hossain, P. P. Sarker, J. Ferdous, M. A. Hannan, M. M. Rahman, D. T. Chu, M. J. Uddin, \u2018Revisiting pharmacological potentials of Nigella sativa seed: a promising option for COVID-19 prevention and cure\u2019, Phytother. Res. 2021, 35, 1329-1344."}, {"Citation": "E. M. F. Barakat, L. M. El Wakeel, R. S. Hagag, \u2018Effects of Nigella sativa on outcome of hepatitis C in Egypt\u2019, World J. Gastroenterol. 2013, 19, 2529-2536."}, {"Citation": "D. K. Verma, P. Kumar, M. El-Shazly, \u2018Unmasking the many faces of Giloy (Tinospora cordifolia L.): a fresh look on its phytochemical and medicinal properties\u2019, Curr. Pharm. Des. 2021, 27, 2571-2581."}, {"Citation": "T. S. Panchabhai, U. P. Kulkarni, N. N. Rege, \u2018Validation of therapeutic claims of Tinospora cordifolia: A review\u2019, Phytother. Res. 2008, 22, 425-441."}, {"Citation": "N. Choudhary, M. Siddiqui, S. Khatoon, \u2018Pharmacognostic evaluation of Tinospora cordifolia (Willd.) Miers and identification of biomarkers\u2019,"}, {"Citation": "Indian J. Tradit. Knowl. 2014, 543-550."}, {"Citation": "M. Manne, G. Goudar, S. R. Varikasuvu, M. C. Khetagoudar, H. Kanipakam, P. Natarajan, M. D. Ummiti, V. A. Yenagi, S. Chinthakindi, P. Dharani, \u2018Cordifolioside: potent inhibitor against M pro of SARS-CoV-2 and immunomodulatory through human TGF-\u03b2 and TNF-\u03b1\u2019, 3 Biotech 2021, 11, 1-25."}, {"Citation": "S. Murugesan, S. Kottekad, I. Crasta, S. Sreevathsan, D. Usharani, M. K. Perumal, S. N. Mudliar, \u2018Targeting COVID-19 (SARS-CoV-2) main protease through active phytocompounds of ayurvedic medicinal plants-Emblica officinalis (Amla), Phyllanthus niruri Linn.(Bhumi Amla) and Tinospora cordifolia (Giloy)-A molecular docking and simulation study\u2019, Comput. Biol. Med. 2021, 136, 104683."}, {"Citation": "P. Leyon, G. Kuttan, \u2018Effect of Tinospora cordifolia on the cytokine profile of angiogenesis-induced animals\u2019, Int. Immunopharmacol. 2004, 4, 1569-1575."}, {"Citation": "Y. Fu, J. Chen, Y.-J. Li, Y.-F. Zheng, P. Li, \u2018Antioxidant and anti-inflammatory activities of six flavonoids separated from licorice\u2019, Food Chem. 2013, 141, 1063-1071."}, {"Citation": "X.-R. WANG, H.-G. HAO, L. CHU, \u2018Glycyrrhizin inhibits LPS-induced inflammatory mediator production in endometrial epithelial cells\u2019, Microb. Pathog. 2017, 109, 110-113."}, {"Citation": "Y. Xiao, J. Xu, C. Mao, M. Jin, Q. Wu, J. Zou, Q. Gu, Y. Zhang, Y. Zhang, \u201818\u03b2-glycyrrhetinic acid ameliorates acute Propionibacterium acnes-induced liver injury through inhibition of macrophage inflammatory protein-1\u03b1\u2019, J. Biol. Chem. 2010, 285, 1128-1137."}, {"Citation": "H. Lu, N. Huo, G. Wang, H. Li, L. Nie, X. Xu, \u2018Clinical observation of therapeutic effect of compound glycyrrhizin on SARS\u2019, China Pharmacy 2001, 10, 521436."}, {"Citation": "W.\u2005H. Organization, \u2018SARS: clinical trials on treatment using a combination of traditional Chinese medicine and Western medicine: report of the WHO International Expert Meeting to review and analyse clinical reports on combination treatment for SARS, 8-10 October 2003, Beijing, People's Republic of China\u2019, 2004."}, {"Citation": "C. Wu, X. Xu, H. Lu, X. Lin, F. Hou, Y. Yu, G. Wang, L. Nie, \u2018Analysis of the chest X-ray manifestations in SARS patients treated with compound glycyrrhizin\u2019, China Pharmacy 1991, 12, 521972."}, {"Citation": "G. Annunziata, M. Sanduzzi Zamparelli, C. Santoro, R. Ciampaglia, M. Stornaiuolo, G. C. Tenore, A. Sanduzzi, E. Novellino, \u2018May polyphenols have a role against coronavirus infection? An overview of In Vitro evidence\u2019, Frontiers in Medicine 2020, 7, 240."}, {"Citation": "V. S. Shaikh, Y. I. Shaikh, K. Ahmed, \u2018A molecular docking study of lopinavir towards SARS-COV-2 target protein\u2019, Eng. Sci. 2020, 12, 113-116."}, {"Citation": "D. Kumar, V. Chandel, S. Raj, B. Rathi, \u2018In silico identification of potent FDA approved drugs against Coronavirus COVID-19 main protease: A drug repurposing approach\u2019, Chem. Biol. Lett. 2020, 7, 166-175."}, {"Citation": "M. W. El-Saadi, T. Williams-Hart, B. A. Salvatore, E. Mahdavian, \u2018Use of in-silico assays to characterize the ADMET profile and identify potential therapeutic targets of fusarochromanone, a novel anti-cancer agent\u2019, In silico pharmacology 2015, 3, 1-20."}, {"Citation": "T. Sumaryada, C. A. Pramudita, \u2018Molecular docking evaluation of some Indonesian's popular herbals for a possible COVID-19 treatment\u2019, Biointerface Res. Appl. Chem. 2021, 11, 9827-9835."}, {"Citation": "Y. I. Shaikh, V. S. Shaikh, K. Ahmed, G. M. Nazeruddin, H. M. Pathan, \u2018The revelation of various compounds found in Nigella sativa L. (Black Cumin) and their possibility to inhibit COVID-19 infection based on the molecular docking and physical properties\u2019, Eng. Sci. 2020, 11, 31-35."}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "7", "Day": "13"}, {"Year": "2022", "Month": "9", "Day": "20"}, {"Year": "2022", "Month": "9", "Day": "21", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "11", "Day": "23", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "9", "Day": "20", "Hour": "13", "Minute": "12"}, {"Year": "2022", "Month": "9", "Day": "20"}], "PublicationStatus": "ppublish", "ArticleIdList": ["36125969", "PMC9538837", "10.1002/cbdv.202200655"]}}], "PubmedBookArticle": []}